Optic Neuritis Treatment Market Size & Share, by Treatment Type (Surgery, Pharmacological), Indication (Optic Neuritis, Neuropathy, Optic Atrophy, Glaucoma, Congenital), End-user (Ambulatory Surgery Centers, Clinics, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 4174
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Optic Neuritis Treatment Market size was over USD 232.1 Million in 2023 and is poised to reach USD 465.54 Million by the end of 2036, growing at around 5.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of optic neuritis treatment is assessed at USD 243.59 Million. The reason behind the growth is impelled by rising incidences of bacterial infections across the globe. Optic neuritis is frequently idiopathic and can occur in combination with infectious disorders such as Lyme disease, and syphilis, since the infection may prompt the immune system to attack the optic nerve as if it were a foreign intruder. As a result, the treatment for optic neuritis becomes crucial to prevent potential optic nerve damage.

The significant increment in the global geriatric population is believed to fuel market growth. For instance, the elderly population is more susceptible to age-related eye diseases such as cataracts, and glaucoma, which may lead to optic neuritis. Ischemic optic neuropathy, which is more common, mostly affects older persons and has an impact on the visual acuity of adults and seniors. Therefore, a significant increment in the global geriatric population is fueling the market.  According to estimates, the number of individuals in the world who are 60 or older will increase to more than 2 billion by 2050.


Optic Neuritis Treatment Market
Get more information on this report: Request Free Sample PDF

Optic Neuritis Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Spiking Cases of Blindness across the Globe- Optic neuritis (ON) is a disorder that affects the eye and your vision when the nerve to the eye gets inflamed. Moreover, blindness or vision loss of one eye is a symptom of optic neuritis and it can be treated with optic neuritis treatment, this drives the growth of the market. The number of people who are losing their vision is rising, and it is predicted that over the next 30 years, eyesight loss is predicted to rise by over 50% across the globe.
  • Growing Cases of Autoimmune Disorders- This autoimmune disorder such as multiple sclerosis causes immune system cells and antibodies to attack the optic nerves and may cause damage. Optic neuritis is a common visual symptom of multiple sclerosis; the lifetime chance of acquiring multiple sclerosis is over 45% following one episode of optic neuritis.

Challenges

  • Side Effects of Treatment such as Weight Gain, Increased Blood Pressure, and Others- This treatment has its benefits however it also does have some side effects which include weight gain, increased blood pressure, and others, which are especially seen in the geriatric population.
  • Lack of Requisite Awareness of the Treatment
  • Increment in the Utilization of Prednisolone Prednisone

Optic Neuritis Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

5.5%

Base Year Market Size (2023)

USD 232.1 Million

Forecast Year Market Size (2036)

USD 465.54 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Optic Neuritis Treatment Segmentation

End-User (Ambulatory Surgery Centers, Clinics, Hospitals)

The hospital segment in the optic neuritis treatment market is estimated to gain a robust revenue share in the coming years owing to the availability of medical device testing, medical professionals in a single place, and a notable patient pool. In addition, hospitals have specialized departments which have the expertise and better resources to provide quality care for optic neuritis patients. Advanced diagnostic tools and around-the-clock medical professionals are also easily available on hospital premises, aiding in the accurate and timely diagnosis of optic neuritis.

Treatment Type (Surgery, Pharmacological)

Optic neuritis treatment market from the pharmacological segment is set to garner a notable share in the near future since pharmacological treatments such as the usage of steroid medications are used to lessen inflammation in the optic nerve and hasten the healing of ocular neuritis. The treatment also includes corticosteroid drugs used to treat optic neuritis, which has proved its efficiency for decades. For instance, for improving visual outcomes in optic neuritis, the use of an oral high-dose corticosteroid is just as effective as a high-dose intravenous corticosteroid. Besides this, pharmacological treatment includes disease-modifying therapies that are widely used to treat optic neuritis cases associated with multiple sclerosis.

Our in-depth analysis of the global market includes the following segments:

Treatment Type

  • Surgery
  • Pharmacological

Indication

  • Optic Neuritis & Neuropathy
  • Optic Atrophy
  • Glaucoma
  • Congenital

End-User

  • Ambulatory Surgery Centers
  • Clinics
  • Hospitals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Optic Neuritis Treatment Industry- Regional Synopsis

North American Market Forecast

Optic neuritis treatment market in North America is predicted to account for the largest share of 35% by the end of 2036 impelled by the higher adoption of steroids. As a result, it may increase access to steroid treatment for optic neuritis in the region. More than 3% of high school seniors in the US have used steroids at least once in their lifetime, and almost half a million youngsters use them annually

APAC Market Statistics

The Asia Pacific optic neuritis treatment market is estimated to be the second largest, during the forecast timeframe led by the growing prevalence of herpes, mumps, and measles. Growing cases of these viral infections may potentially result in optic neuritis in a higher number of individuals in the region. Since it is a secondary condition resulting from the immune response to the viral infection which can cause inflammation in the optic nerve. For instance, in countries like Sri Lanka, China, and others, more than 95% of children up to 23 months old were observed to be immunized against measles.

Research Nester
Optic-Neuritis-Treatment-Market-Regional
Get more information on this report: Request Free Sample PDF

Companies Dominating the Optic Neuritis Treatment Landscape

    • Santen Pharmaceutical Co., Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mallinckrodt plc
    • AbbVie Inc.
    • Novartis AG
    • Sanofi-aventis Groupe
    • AdvoCare International
    • Hikma Pharmaceuticals PLC
    • Henry Schein, Inc.
    • Fresenius Kabi USA
    • Pfizer Inc.

     


In the News

  • Novartis AC to acquire European Commission Approval for Tabrecta, lapatinib, to cure small cell lung cancer. Tabrecta also provides specialized therapy for cured patients living with NSCLC.
  • Hikma Pharmaceuticals PLC to announce to completion of the acquisition of Custopharm Inc. The company is acquired from Water Street Healthcare Partners by getting approval from the US Federal Trade Commission.

Author Credits:  Radhika Pawar


  • Report ID: 4174
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of optic neuritis treatment is assessed at USD 243.59 Million.

The optic neuritis treatment market size was over USD 232.1 Million in 2023 and is poised to reach USD 465.54 Million by the end of 2036, growing at around 5.5% CAGR during the forecast period i.e., between 2024-2036. Rising incidences of bacterial infections across the globe and the significant increment in global geriatric population are the major factors driving the growth of the market.

North America is predicted to account for the largest share of 35% by 2036, impelled by higher adoption of steroids in the region.

Santen Pharmaceutical Co., Ltd., Mallinckrodt plc, AbbVie Inc., Novartis AG, Sanofi-aventis Groupe, AdvoCare International, Hikma Pharmaceuticals PLC, Henry Schein, Inc., Fresenius Kabi USA, Pfizer Inc.

In the year 2024, the industry size of optic neuritis treatment is assessed at USD 243.59 Million.
Optic Neuritis Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample